IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils.

abstract：:Granulysin is a protein present in the granules of human cytotoxic T lymphocytes (CTL) and natural killer (NK) cells, with cytolytic activity against microbes and tumors. Previous work demonstrated the therapeutic effect of intratumoral injection of recombinant granulysin using in vivo models of breast cancer and mult...

journal_title：Oncoimmunology

authors： Ibáñez-Pérez R,Guerrero-Ochoa P,Al-Wasaby S,Navarro R,Tapia-Galisteo A,De Miguel D,Gonzalo O,Conde B,Martínez-Lostao L,Hurtado-Guerrero R,Sanz L,Anel A

更新日期：2019-07-22 00:00:00

abstract：:The immune system avoids oncogenesis and slows down tumor progression through a mechanism called immunosurveillance. Nevertheless, some malignant cells manage to escape from immune control and form clinically detectable tumors. Tetraploidy, which consists in the intrinsically unstable duplication of the genome, is con...

journal_title：Oncoimmunology

authors： Aranda F,Chaba K,Bloy N,Garcia P,Bordenave C,Martins I,Stoll G,Tesniere A,Kroemer G,Senovilla L

更新日期：2018-05-21 00:00:00

abstract：:Agonistic tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-receptor-specific antibodies are attractive antitumor therapeutics. Recently, our group has generated several human monoclonal antibodies (mAbs) to TRAIL-receptor-1 (TRAIL-R1) (TR1-IgGs) using ISAAC technology. However, these TR1-IgGs did ...

journal_title：Oncoimmunology

authors： Piao X,Ozawa T,Hamana H,Shitaoka K,Jin A,Kishi H,Muraguchi A

更新日期：2016-05-04 00:00:00

abstract：:Vaccines designed to abrogate the tolerance of tumor self-antigens and amplify cytotoxic CD8+ T cells (CTLs) have promise for the treatment of cancer. Type I natural killer (NKT) cells have attracted considerable interest in the cancer therapy field. In the current study, we have exploited the unique ability of NKT ce...

journal_title：Oncoimmunology

authors： Ghinnagow R,De Meester J,Cruz LJ,Aspord C,Corgnac S,Macho-Fernandez E,Soulard D,Fontaine J,Chaperot L,Charles J,Soncin F,Mami-Chouaib F,Plumas J,Faveeuw C,Trottein F

更新日期：2017-08-18 00:00:00

abstract：:The versatility and plasticity of myeloid cell polarization/differentiation has turned out to be crucial in health and disease, and has become the subject of intense investigation during the last years. On one hand, myeloid cells provide a critical contribution to tissue homeostasis and repair. On the other hand, myel...

journal_title：Oncoimmunology

authors： Schouppe E,De Baetselier P,Van Ginderachter JA,Sarukhan A

更新日期：2012-10-01 00:00:00

abstract：:Dietary interventions have a profound impact on whole body metabolism, including oncometabolism (the metabolic features allowing cancer cells to proliferate) and immunometabolism (the catabolic and anabolic reactions that regulate immune responses). Recent preclinical studies demonstrated that multiple dietary changes...

journal_title：Oncoimmunology

authors： Lévesque S,Pol JG,Ferrere G,Galluzzi L,Zitvogel L,Kroemer G

更新日期：2019-04-03 00:00:00

abstract：:Necrotic cells are known to activate the innate immune system and trigger inflammation by releasing damage associated molecular patterns (DAMPs). However, how necrotic cells influence the induction of antigen-specific CD8(+) T cell-mediated adaptive immune responses under sterile conditions, in the absence of pathogen...

journal_title：Oncoimmunology

authors： Gamrekelashvili J,Ormandy LA,Heimesaat MM,Kirschning CJ,Manns MP,Korangy F,Greten TF

更新日期：2012-10-01 00:00:00

abstract：:Low expression of RhoGDI2 is associated with poor outcome in cancer patients. In animal models, RhoGDI2 suppresses lung metastasis by reducing the expression of the proteoglycan versican, whose levels portend poor patient prognosis. Versican promotes metastasis through enhanced tumor migration and creation of an infla...

journal_title：Oncoimmunology

authors： Said N,Theodorescu D

更新日期：2012-10-01 00:00:00

abstract：:HSP110 is induced by different stresses and, through its anti-apoptotic and chaperoning properties, helps the cells to survive these adverse situations. In colon cancers, HSP110 is abnormally abundant. We have recently showed that colorectal cancer (CRC) patients with microsatellite instability (MSI) had an improved r...

journal_title：Oncoimmunology

authors： Berthenet K,Boudesco C,Collura A,Svrcek M,Richaud S,Hammann A,Causse S,Yousfi N,Wanherdrick K,Duplomb L,Duval A,Garrido C,Jego G

更新日期：2016-04-22 00:00:00

abstract：:Myeloid derived suppressor cells (MDSC) suppress anti-tumor immune responses. Our recent publication provides evidence that SHIP-1 plays a prominent role in pancreatic tumor development by regulating MDSC. Therefore, SHIP-1 may be a potential therapeutic target for the treatment of MDSC-related hematological malignanc...

journal_title：Oncoimmunology

authors： Ghansah T

更新日期：2012-09-01 00:00:00

abstract：:Oncology treatment has been revolutionized by the introduction of immune checkpoint inhibitor drugs, which enable 20-40% of patients to generate anti-tumor immune responses. Combination treatment approaches with chemotherapeutic drugs may enable responses in the remaining patient cohorts. In this regard, a handful of ...

journal_title：Oncoimmunology

authors： Bauzon M,Drake PM,Barfield RM,Cornali BM,Rupniewski I,Rabuka D

更新日期：2019-01-22 00:00:00

abstract：:Oncolytic virotherapy is emerging as a promising approach for the treatment of several neoplasms. The term "oncolytic viruses" is generally employed to indicate naturally occurring or genetically engineered attenuated viral particles that cause the demise of malignant cells while sparing their non-transformed counterp...

journal_title：Oncoimmunology

authors： Vacchelli E,Eggermont A,Sautès-Fridman C,Galon J,Zitvogel L,Kroemer G,Galluzzi L

更新日期：2013-06-01 00:00:00

abstract：:MDR1 is an ATP-dependent transmembrane transporter primarily studied for its role in the detoxification of tissues and for its implication in resistance of tumor cells to chemotherapy treatment. Several studies also report on its expression on immune cells where it plays a protective role from xenobiotics and toxins. ...

journal_title：Oncoimmunology

authors： Bossennec M,Di Roio A,Caux C,Ménétrier-Caux C

更新日期：2018-09-06 00:00:00

abstract：:Dendritic cell (DC)-based vaccines against cancer have been extensively developed over the past two decades. Typically DC-based cancer immunotherapy entails loading patient-derived DCs with an appropriate source of tumor-associated antigens (TAAs) and efficient DC stimulation through a so-called "maturation cocktail" ...

journal_title：Oncoimmunology

authors： Garg AD,Vara Perez M,Schaaf M,Agostinis P,Zitvogel L,Kroemer G,Galluzzi L

更新日期：2017-05-12 00:00:00

abstract：:Chronic inflammation can result from inadequate engagement of resolution mechanisms, mainly accomplished by specialized pro-resolving mediators (SPMs) arising from the metabolic activity of lipoxygenases (ALOX5/15) on ω-6 or ω-3 essential polyunsaturated fatty acids (PUFA). We previously demonstrated that formyl pepti...

journal_title：Oncoimmunology

authors： Prevete N,Liotti F,Illiano A,Amoresano A,Pucci P,de Paulis A,Melillo RM

更新日期：2017-02-21 00:00:00

abstract：:Blockade of the PD-1 receptor has revolutionized the treatment of metastatic melanoma, with significant increases in overall survival (OS) and a dramatic improvement in patient quality of life. Despite the success of this approach, the number of benefitting patients is limited and there is a need for predictive biomar...

journal_title：Oncoimmunology

authors： Pico de Coaña Y,Wolodarski M,van der Haar Àvila I,Nakajima T,Rentouli S,Lundqvist A,Masucci G,Hansson J,Kiessling R

更新日期：2020-08-28 00:00:00

abstract：:The functional status of CD4(+) T cells is a critical determinant of antitumor immunity. Polyfunctional CD4(+) T cells possess the ability to concomitantly produce multiple Th1-type cytokines, exhibiting a functional attribute desirable for cancer immunotherapy. However, the mechanisms by which these cells are induced...

journal_title：Oncoimmunology

authors： Ding ZC,Liu C,Cao Y,Habtetsion T,Kuczma M,Pi W,Kong H,Cacan E,Greer SF,Cui Y,Blazar BR,Munn DH,Zhou G

更新日期：2016-04-25 00:00:00

abstract：:Human papillomavirus (HPV) infection is one of the most important etiologic causes of oropharyngeal head and neck squamous cell carcinoma (HNSCC). Patients with HPV-positive HNSCC were reported to have a better clinical outcome than patients with HPV-negative cancers. However, little is known about the possible causes...

journal_title：Oncoimmunology

authors： Partlová S,Bouček J,Kloudová K,Lukešová E,Zábrodský M,Grega M,Fučíková J,Truxová I,Tachezy R,Špíšek R,Fialová A

更新日期：2015-01-30 00:00:00

abstract：:A missense mutation in RHOA encoding p.Gly17 Val has been reported to occur frequently in angioimmunoblastic T-cell lymphoma (AITL). Here, we describe a murine model which expresses the human RHOA mutant gene product in a T-cell specific manner and develops AITL-like symptoms. Most transgenic mice feature with latency...

journal_title：Oncoimmunology

authors： Lee GJ,Jun Y,Yoo HY,Jeon YK,Lee D,Lee S,Kim J

更新日期：2020-05-13 00:00:00

abstract：:Type I interferon (IFN) release by irradiated cancer cells is paramount for radiation therapy to elicit anticancer immunity. Our findings demonstrate that mitochondrial outer membrane permeabilization (MOMP) triggered by RT enables exposure of mitochondrial DNA to the cytosol, hence setting off CGAS-driven type I IFN ...

journal_title：Oncoimmunology

authors： Yamazaki T,Galluzzi L

更新日期：2020-07-22 00:00:00

abstract：:Regressing tumors are usually associated with a large immune infiltrate, but the molecular and cellular interactions that govern a successful anti-tumor immunity remain elusive. Here, we have triggered type I Interferon (IFN) signaling in a breast tumor model (MMTV-PyMT) using 5,6-dimethylxanthenone-4-acetic acid (DMX...

journal_title：Oncoimmunology

authors： Weiss JM,Guérin MV,Regnier F,Renault G,Galy-Fauroux I,Vimeux L,Feuillet V,Peranzoni E,Thoreau M,Trautmann A,Bercovici N

更新日期：2017-07-07 00:00:00

abstract：:We report long-term clinical outcomes and immune responses observed from a phase 1 trial of agonist CD40 monoclonal antibody (mAb) and blocking CTLA-4 mAb in patients with metastatic melanoma. Twenty-four patients previously untreated with checkpoint blockade were enrolled. The agonistic CD40 mAb CP-870,893 and the CT...

journal_title：Oncoimmunology

authors： Bajor DL,Mick R,Riese MJ,Huang AC,Sullivan B,Richman LP,Torigian DA,George SM,Stelekati E,Chen F,Melenhorst JJ,Lacey SF,Xu X,Wherry EJ,Gangadhar TC,Amaravadi RK,Schuchter LM,Vonderheide RH

更新日期：2018-08-20 00:00:00

abstract：:Esophageal cancer-related gene 4 (Ecrg4), a hormone-like peptide, is thought to be a tumor suppressor, however, little is known about the mechanism of how Ecrg4 suppresses tumorigenesis. Here, we show that the ecrg4 null glioma-initiating cell (GIC) line, which was generated from neural stem cells of ecrg4 knockout (K...

journal_title：Oncoimmunology

authors： Moriguchi T,Kaneumi S,Takeda S,Enomoto K,Mishra SK,Miki T,Koshimizu U,Kitamura H,Kondo T

更新日期：2016-10-14 00:00:00

abstract：:Surgical resection is the mainstay of treatment for solid tumors, but the postoperative period is uniquely inclined to the formation of metastases, largely due to the suppression of natural killer (NK) cells. We found that preoperative influenza vaccination prevents postoperative NK-cell dysfunction, attenuating tumor...

journal_title：Oncoimmunology

authors： Tai LH,Zhang J,Auer RC

更新日期：2013-11-01 00:00:00

abstract：:Macrophages promote the growth of leiomyosarcoma (LMS), a malignant soft-tissue tumor. CD47 on tumor cells binds to the macrophagic receptor signal regulatory protein α (SIRPα) and prevents phagocytosis. We showed that anti-CD47 monoclonal antibodies (mAbs) allow macrophages to engulf LMS cells and prevent tumor growt...

journal_title：Oncoimmunology

authors： Edris B,Weiskopf K,Weissman IL,van de Rijn M

更新日期：2012-10-01 00:00:00

abstract：:Ibrutinib, a BTK inhibitor, is currently used to treat various hematological malignancies. We evaluated whether ibrutinib treatment during development of murine bone marrow-derived dendritic cells (DCs) modulates their maturation and activation. Ibrutinib treatment increased the proportion of CD11c(+) DCs, upregulated...

journal_title：Oncoimmunology

authors： Natarajan G,Oghumu S,Terrazas C,Varikuti S,Byrd JC,Satoskar AR

更新日期：2016-03-10 00:00:00

abstract：:We have recently reported that the PD-1 and CTLA4 signaling pathways are active in both effector and regulatory T cells, causing profound immune dysfunctions in the tumor microenvironment. In line with this notion, the dual blockade of PD-1- and CTLA4-conveyed signals may exert robust therapeutic effects. Here, we dis...

journal_title：Oncoimmunology

authors： Duraiswamy J,Freeman G,Coukos G

更新日期：2013-10-01 00:00:00

abstract：:Antitumor cytotoxic T lymphocytes (CTLs) are essential for immune surveillance, yet the blockade of eliciting such CTLs during oncolytic virotherapy remains incompletely understood. Here, we show that oncolysis of mesothelioma by modified vaccinia Tiantan (MVTT) induces damage-associated molecular patterns exposure. A...

journal_title：Oncoimmunology

authors： Tan Z,Liu L,Chiu MS,Cheung KW,Yan CW,Yu Z,Lee BK,Liu W,Man K,Chen Z

更新日期：2018-10-16 00:00:00

abstract：:Innate immunity serves as a first line of defense against infectious agents, and germ-line-encoded pattern recognition receptors detect stressed and infected cells and elicit potent effector activities that accomplish efficient microbe containment. Recent evidence demonstrates that these pattern-sensing systems are al...

journal_title：Oncoimmunology

authors： Jinushi M

更新日期：2012-03-01 00:00:00

abstract：INTRODUCTION:Vaccination with dendritic cells (DCs) has generally not fulfilled its promise in cancer immunotherapy due to ineffective translation of immune responses into clinical responses. A proposed reason for this is intrinsic immune regulatory mechanisms, such as regulatory T cells (Tregs). A metronomic regimen o...

journal_title：Oncoimmunology

authors： Borch TH,Engell-Noerregaard L,Zeeberg Iversen T,Ellebaek E,Met Ö,Hansen M,Andersen MH,Thor Straten P,Svane IM

更新日期：2016-07-08 00:00:00